Clinical Trial: A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar(R) in Participants With Schizophrenia

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07722728) titled 'A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar(R) in Participants With Schizophrenia' on July 15.

Brief Summary: The study is to evaluate the pharmacokinetic profile of B2227 Extended-Release Injectable Suspension against Vraylar(R) Cariprazine capsules of AbbVie Inc. in participants with schizophrenia.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Schizophrenia

Intervention: DRUG: 30 mg B2227

Single-dose; Subcutaneous

DRUG: 70 mg B2227

Single-dose; Subcutaneous

DRUG: 150 mg B2227

Single-dose; Subcutaneous

DRUG: Vraylar(R)...